Gilead has a Memorandum of Understanding (MoU) with the World Health Organization (WHO) to provide AmBisome® (liposomal amphotericin B) at no profit to developing world countries for the treatment of mucosal and visceral leishmaniasis. It is estimated that visceral leishmaniasis affects 500,000 people annually, with the number of deaths ranging from 60,000 to 200,000. The majority of cases occur in Bangladesh, Nepal, India, Brazil, and Sudan.
|Location||South Asia, Sudan, India, Brazil, Bangladesh, North Africa and Middle East, Latin America and Caribbean|
|Value||USD 8 Million|